BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38527258)

  • 21. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
    Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
    Eggermont AM
    Eur J Cancer; 2016 Dec; 69():39-42. PubMed ID: 27816830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
    Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
    Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.
    Stege H; Haist M; Nikfarjam U; Schultheis M; Heinz J; Pemler S; Loquai C; Grabbe S
    Target Oncol; 2021 Sep; 16(5):537-552. PubMed ID: 34554353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The extent of surgery for stage III melanoma: how much is appropriate?
    Franke V; van Akkooi ACJ
    Lancet Oncol; 2019 Mar; 20(3):e167-e174. PubMed ID: 30842060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal systemic therapy for high-risk resectable melanoma.
    Eggermont AMM; Hamid O; Long GV; Luke JJ
    Nat Rev Clin Oncol; 2022 Jul; 19(7):431-439. PubMed ID: 35468949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
    Tarhini A; Lin Y; Lin H; Rahman Z; Vallabhaneni P; Mendiratta P; Pingpank JF; Holtzman MP; Yusko EC; Rytlewski JA; Rao UNM; Ferris RL; Kirkwood JM
    J Immunother Cancer; 2018 Oct; 6(1):112. PubMed ID: 30352626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Therapy in Melanoma: Where Are We Now?
    Saad M; Tarhini AA
    Curr Oncol Rep; 2023 Apr; 25(4):325-339. PubMed ID: 36781621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting.
    Tétu P; Baroudjian B; Lebbe C
    Curr Opin Oncol; 2020 Mar; 32(2):85-90. PubMed ID: 31895121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
    Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
    Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
    Weber J; Glutsch V; Geissinger E; Haug L; Lock JF; Schneider F; Kneitz H; Goebeler M; Schilling B; Gesierich A
    Br J Dermatol; 2020 Sep; 183(3):559-563. PubMed ID: 31773720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
    ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
    Mojtahed SA; Boyer NR; Rao SA; Gajewski TF; Tseng J; Turaga KK
    Ann Surg Oncol; 2021 Dec; 28(13):9039-9047. PubMed ID: 34129153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
    Reijers ILM; Menzies AM; van Akkooi ACJ; Versluis JM; van den Heuvel NMJ; Saw RPM; Pennington TE; Kapiteijn E; van der Veldt AAM; Suijkerbuijk KPM; Hospers GAP; Rozeman EA; Klop WMC; van Houdt WJ; Sikorska K; van der Hage JA; Grünhagen DJ; Wouters MW; Witkamp AJ; Zuur CL; Lijnsvelt JM; Torres Acosta A; Grijpink-Ongering LG; Gonzalez M; Jóźwiak K; Bierman C; Shannon KF; Ch'ng S; Colebatch AJ; Spillane AJ; Haanen JBAG; Rawson RV; van de Wiel BA; van de Poll-Franse LV; Scolyer RA; Boekhout AH; Long GV; Blank CU
    Nat Med; 2022 Jun; 28(6):1178-1188. PubMed ID: 35661157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.